The precise role of 5'AMP-activated kinase (AMPK) in cancer and its potential as a therapeutic target is controversial. While it is well established that activation of this energy sensor inhibits the main anabolic processes that sustain cancer cell proliferation and growth, AMPK activation can confer on cancer cells the plasticity to survive under metabolic stress such as hypoxia and glucose deprivation, which are commonly observed in fast growing tumors. Thus, AMPK is referred to as both a "conditional" tumor suppressor and "contextual" oncogene. To add a further layer of complexity, AMPK activation in human cancer tissues and its correlation with tumor aggressiveness and progression appears to vary in different contexts. The current review discusses the different faces of this metabolic regulator, the therapeutic implications of its modulation and provides an overview of the most relevant data available on AMPK activation and AMPK activating drugs in human studies.
Introduction
5' AMP-activated kinase (AMPK) is a central metabolic sensor that stands at the crossroad between metabolic and signaling networks. In 2003, the discovery of the tumor suppressor liver kinase B1 (LKB1) as the major upstream kinase of AMPK established a link between an energy regulator and cancer pathogenesis, suggesting that the tumor suppressor functions of LKB1 could be mediated by AMPK (1) (2) (3) . Since then, in vitro and in vivo studies have been conducted to dissect the role of AMPK in cancer initiation and progression, using AMPK modulating drugs. The functional consequences of AMPK activation in cancer appear to be much more complex than initially thought and AMPK can behave as both cancer "friend" or "foe" in a context-specific manner.
Drug-induced supra-physiological activation of AMPK reduces tumor growth in vitro and in preclinical models through the suppression of key biosynthetic pathways (reviewed in (4, 5) ). However, physiological activation of AMPK in response to a broad range of stresses (e.g. hypoxia, glucose deprivation, and matrix detachment) provide cancer cells with the flexibility to adapt and survive metabolic stress (metabolic adaptation) (reviewed in (6) ). Immunohistochemical evaluation of AMPK status in human tissues has revealed that the levels of AMPK activation are heterogeneous in different tumor types, while discordant data have been reported on the correlation between AMPK activation and tumor prognosis.
Here, we discuss the "two faces" of AMPK, the therapeutic benefit of AMPK modulators and we review the current data available on AMPK activation and AMPK activating drugs in human studies.
Throughout the review, we will associate AMPK with both the terms "tumor promoter" and "tumor suppressor". However, we do not intend to define AMPK as a classical bona fide tumor suppressor gene such as LKB1, which is mutated or deleted in several cancers, rather to emphasize the fact that AMPK activation may result in tumor growth inhibition, cell cycle arrest, and apoptosis of cancer cells in some tumor types/contexts. Interrogating the cBioPortal data, the frequency of mutation/deletion in the genes (reviewed in (13) ). However, CaMKK2 can compensate for the absence of LKB1 in mediating AMPK phosphorylation (15) . In addition to AMP, ADP and Ca2+, recent studies have also identified reactive oxygen species (ROS) as additional upstream activators of AMPK, acting in an LKB1-independent manner (16) (Fig. 1) . Once activated, AMPK maintains energy balance by switching off anabolic pathways that consume ATP and NADPH, while switching on catabolic pathways that generate ATP both by direct phosphorylation of metabolic enzymes, and through longer-term effects mediated by phosphorylation of transcription factors and co-activators (14) . Thus AMPK can restrain cell growth by: Yes-associated protein (YAP) (13, 17, 18) ], while promoting cell survival mechanisms during metabolic stress (19) , as discussed below (Fig. 2) .
Role of AMPK in cancer: pre-clinical studies

AMPK as a tumor suppressor
Since the role of LKB1 as tumor suppressor was well established, AMPK was primarily considered as a component of the LKB1-mediated tumor suppressor cascade and much less was known regarding its own independent role in cancer. This was due to the fact that most of the data were generated utilizing the AMPK activators AICAR and metformin, which also display AMPK-independent mechanisms or by experimental evidence in models of LKB1 inactivation, which affect an additional 12 AMPK-related downstream kinases, beyond AMPK. The role of the AMPK-related kinases is still not very well characterized, though they might themselves contribute to the tumor suppressive functions of LKB1, as well as have independent functions (20) . Experiments of genetic ablation of AMPK, the use of direct AMPK activators, and detailed phosphorylation studies in different cancer models have recently helped to address this issue. Faubert et al. have reported that the ubiquitous knockout (KO) of AMPKα1, the only catalytic subunit expressed in B cells, accelerates the development of lymphomas in transgenic mice overexpressing c-Myc, suggesting that AMPK loss can cooperate with oncogenic drivers to promote tumorigenesis in a tissue-specific manner. The underpinning mechanism for AMPK tumor suppressor activity is the ability of the kinase to exert an "anti-Warburg" effect by downregulating hypoxia-inducible factor 1-alpha (HIF-1α) and its downstream glycolytic genes, which conversely are upregulated in AMPKα1 KO mice (21) .
Aside from antagonizing the Warburg effect, AMPK has also been shown to exert its ''metabolic'' tumor-suppressor role by inhibiting unchecked mTORC1 activity and de novo lipogenesis, required both during G1/S and G2/M phases. We have recently observed increased de novo fatty acid (FA) synthesis concomitant to reduced AMPK activation and phosphorylation of its major target ACC1 (the rate-limiting enzyme for FA synthesis), prior to cytokinesis initiation. In this view, by inhibiting de novo FA synthesis and FA incorporation into membranes, activation of AMPK would prevent cells from completing mitosis, arresting them at a "lipogenic" G2/M checkpoint. This was indeed observed under direct supra-physiological activation of AMPK (22) . Cell cycle arrest (via decreased fraction of cells in the S phase) and/or apoptosis, was previously confirmed using ACC1 and fatty acid synthase (FASN) siRNA to directly inhibit FA synthesis (23, 24) .
AMPK also plays a direct metabolic-independent role in cell cycle regulation (25) (26) (27) . A finetuned biphasic activation of AMPK has been shown to be required for proper mitotic progression (28) .
However, alteration of the dynamic spatial and temporal regulation of AMPK by either its sustained activation or depletion can result in microtubule misalignment, spindle misorientation, abnormal chromosome segregation followed by mitotic catastrophe and polyploidy (e.g. observed under metformin treatment) or mitotic delay (e.g. observed in AMPK-silenced cells) (27, 29) . Thus, cell cycle arrest induced by persistent supra-physiological activation of AMPK could be ascribed to both the inhibition of de novo FA synthesis (metabolic role) as well as mitotic spindle assembly/chromosome segregation abnormalities (non-metabolic role). Recently, a role for the subunit AMPK α1 in the direct regulation of cell cycle, independently of energy balance, has also emerged (30) .
A third mechanism in favor of AMPK's behavior as a "tumor suppressor" has been described by destabilization, leading to hyperactivation of YAP (18) . Finally, AMPK may be inactivated by its ubiquitination and degradation by the cancer-specific MAGE-A3/6-TRIM28 ubiquitin ligase. MAGE-A3 and MAGE-A6 proteins, normally expressed only in the male germline, are frequently re-activated in human cancers, they are necessary for cancer cell viability, and sufficient to induce cell transformation. Screening for targets of MAGE-A3/6-TRIM28 complex revealed that it ubiquitinates and degrades AMPKα1, leading to inhibition of autophagy, activation of mTORC1 signaling, and hypersensitization to AMPK agonists, such as metformin. These findings elucidated a germline mechanism commonly hijacked in cancer to suppress AMPK (33) .
Further evidence also supports the tumor suppressor role of AMPK in some tumor types and genetic contexts. First, protein kinase B (Akt), has been reported to induce AMPK phosphorylation at Ser485, reducing its activation by LKB1 (34) . This might occur in tumors in which Akt is hyperactivated due to phosphatase and tensin homolog (PTEN) loss-of-function mutations, or activating mutations in phosphoinositide-3-kinase (PI3K). Second, AMPK activation is suppressed in melanoma cells carrying the most common BRAF mutation V600E, which induces a constitutively active downstream ERK. The lack of AMPK activity is due to ERK and ribosomal S6 kinase (RSK)-mediated phosphorylation of LKB1, which prevents its binding/activation of AMPK. These data suggested that suppression of LKB1/AMPK pathway might play an important role in BRAF V600E-driven tumorigenesis (35) . Third, inhibition of AMPK has been observed in a PTEN-deficient model of thyroid cancer and in NSCLC cells expressing the mitochondrial heat shock protein 90 chaperone TRAP-1 (36).
Fourth, in fumarate hydratase-deficient kidney tumors and cell lines from patients with hereditary leiomyomatosis renal cell cancer (HLRCC), which are characterized by a metabolic shift to aerobic glycolysis, AMPK levels are decreased. AMPK reduction leads to diminished expression of the DMT1 iron transporter, cytosolic iron deficiency, and activation of the iron regulatory proteins, IRP1 and IRP2, resulting in increased expression of HIF-1α. Silencing of HIF-1α or activation of AMPK diminishes invasive activities of the HLRCC cell line UOK262, indicating that overexpression of HIF-1α and downregulation of AMPK contribute to the oncogenic growth of fumarate hydratase-deficient cells (37) . Recently, a study from Rodriguez et al. showed that Cytochrome P450-1A1, constitutively expressed in the majority of breast cancer tumors, promotes breast cancer proliferation and survival, at least in part, through suppression of AMPK signaling (38) . Finally, reduced expression of the catalytic α2 subunit has been reported in some cases of hepatocellular carcinomas and it is associated with enhanced tumor cell growth in mouse xenografts (10) .
Taken together, these results suggest that in specific genetic, metabolic, and signaling contexts, AMPK can exert a tumor suppressor role (Fig. 3 ).
AMPK as contextual tumor promoter
The ability to survive in conditions of metabolic stress, such as hypoxia/nutrient deprivation, or matrix detachment is fundamental to cancer cells. Several mechanisms by which the AMPK pathway supports this plasticity have been described. These include: (i) the induction of autophagy by AMPKdependent phosphorylation of the unc-51-like kinases (ULK) (39), (ii) the promotion of FA oxidation (FAO) to generate ATP (40, 41) , (iii) transcriptional changes induced by phosphorylation of the core histone H2B (42), (iv) the increase of intracellular NADPH levels through the activation of FAO/inhibition of FA synthesis to neutralize cytotoxic ROS (43) (Fig. 3) . Intriguingly, while in nutrientreplete conditions, the AMPK energy-sensing pathway and the PI3K/Akt cascade converge on mTOR with opposing regulatory effects, under glucose depletion, both AMPK and Akt are activated and coordinately support cell survival (44) . Thus, whereas the LKB1/AMPK pathway can act as a tumor suppressor through its ability to restrain tumor growth, it can also behave as "tumor promoter", allowing tumor cells to be more resistant to metabolic stress, such as when tumor growth exceeds the capacity of its blood supply to deliver oxygen and nutrients (Fig. 4) . Recent experimental evidence in vitro, using the direct AMPK activator A-769662, indeed supports this notion (45) . AMPK activation can also 
The therapeutic benefit of AMPK modulators: the metformin paradox
The better understanding of the dichotomous role of AMPK in cancer has also brought about the careful re-evaluation of the use of AMPK modulators in cancer therapy. In this regard, the case of metformin is emblematic.
The interest in using AMPK activators began as evidence was accumulating for the antitumorigenic role of the LKB1/AMPK axis. The anti-proliferative and growth-suppressing effects of supra-physiological activation of AMPK have been shown in vitro and in pre-clinical models. Activation was achieved with natural compounds, the AMP mimetic drug AICAR as well as the biguanides metformin and phenformin, which inhibit complex I of the mitochondrial electron transport chain, leading to increased levels of intracellular ADP, AMP, and energy stress (reviewed in (4, 14, 51)) Metformin has received particular attention since it is a safe medication, used as first choice in the treatment of type II diabetes and has been associated with reduced cancer incidence in diabetic patients (52) . Thus, it is currently being tested for cancer treatment/prevention in several clinical trials, as discussed below. However, ascribing metformin's anti-tumor properties in vivo to AMPK activation has been criticized since the major effect of the drug is the inhibition of hepatic gluconeogenesis, resulting in reduced circulating levels of glucose and insulin, two well-known promoters of tumor cell proliferation. This is also valid for metformin's anti-tumor effects in vitro, where several AMPK-independent mechanisms have been described (45, (53) (54) (55) (56) . Moreover, the discovery of the so-called "biguanide paradox" has recently suggested that, in specific contexts, metformin-mediated suppression of tumor growth does not depend on AMPK activation but, rather, on its down-regulation. Because cells with a defective LKB1/AMPK pathway are less able to restore ATP levels in response to metabolic stress induced by metformin treatment, LKB1/AMPK-deficient cancer cells are more susceptible to cell death than their counterparts with a functional LKB1/AMPK axis (Fig. 5) . Several in vitro and in vivo studies using metformin, phenformin, or other compounds that cause metabolic stress (AICAR, salicylate, and 2-deoxyglucose) have supported this mechanism (discussed in (57, 58) ). In light of this, the use of biguanides may be most effective in combination with agents that inhibit, rather than activate, AMPK and, overall, these data suggest that the use of AMPK inhibitors rather than activators would preferentially trigger cancer cell death in the context of metabolic stress. Interestingly, the chemotherapeutic agent sunitinib has been shown to inhibit AMPK, suggesting that combinatorial treatment of sunitinib and metformin could be clinically relevant (59) .
Novel direct AMPK activators have been developed to overcome the off-target effects of metformin and AICAR treatment. The direct activator A-769662 (which binds the β1 subunit) delays tumor formation in PTEN null/LKB1 hypomorphic mice (60) . The same compound has been shown to suppress the proliferation of breast, colon, and prostate cancer cells (61) (62) (63) . A-769662 was however ineffective in models of glioma (56) . OSU-53, a direct activator that binds the auto-inhibitory domain of AMPK, displays tumor growth inhibition in vitro and in vivo in triple-negative breast cancer models (64) . The same group reported that AMPK activation by OSU-53 blocks "EMT" in breast and prostate cancer cells by activating Foxo3a, which results in the inhibition of invasive phenotypes in vitro and metastatic properties in vivo (32). Direct supra-physiological activation of AMPK in nutrient-replete conditions has been also shown to suppress prostate cancer cells growth, in association with mitotic arrest and apoptosis, and to potentiate the effect of anti-androgens in vitro (65) . The inhibitory effect of AMPK activation on the androgen receptor (AR) axis at both transcriptional and post-translational levels was previously observed when a supra-physiological activation of AMPK was achieved by treatment with metformin or AICAR (66, 67) . Finally, Compound 1, a novel AMPK activator, induces a significant antitumor activity in vitro and tumor growth delay in a mouse xenograft model of colorectal cancer (68) . The mechanism through which Compound 1 activates AMPK, is however, still uncharacterized.
Taken together, the induction of a persistent, supra-physiological activation of AMPK results in tumor suppression in some cancer types (Fig. 3) .
Salicylate, the active metabolite of aspirin following absorption from the gut, was recently identified as a direct AMPK activator, which binds to the same site on the β1 subunit as A-769662 (69).
This suggests that AMPK activation might be involved in mediating aspirin's protective effects against cancer. Future pre-clinical studies in genetically engineered AMPK models are however required to validate this hypothesis.
Overall, these apparently conflicting data suggest that both AMPK activators and inhibitors can provide therapeutic benefit in different tumor types, different genetic/metabolic contexts, and different microenvironment conditions. Thus, the choice of AMPK modulators may be different at various phases of tumorigenesis/tumor progression. (70) . Therefore, analysis of AMPK activity and ACC phosphorylation in human tissues should be interpreted with caution.
AMPK role in cancer: Human studies
AMPK activation in human cancers
AMPK activation has been investigated in fresh frozen and archival tumor tissue from numerous cancer sites, including prostate (63, 71, 72) , breast (73, 74) , head and neck (75) , colorectal (76, 77) , gastric (78, 79) , liver (80), lung (81) (82) (83) , ovary (84) , and kidney (85, 86) . Table 1 (81), and kidney (85, 86) cancer patients either within the entire study population or within subgroups. Consistent with the findings for p-AMPKα1 at Thr172, one additional study of lung cancer found that higher expression of p-AMPKα1 at Ser485, which inhibits AMPK signaling (14) , was associated with shorter survival (82) . Conversely, two studies in gastric cancer (78) and in prostate cancer (72) reported associations between higher p-AMPKα1 and disease recurrence; however, the gastric cancer study population was substantially smaller than that of Kim et al. (79) . Three additional studies in lung (83) and breast cancer patients (73, 74) found no association between p-AMPKα1 expression and overall survival. In cross-sectional analyses, higher p-AMPKα1 expression was specimens (63) . Overall, these human studies support the hypothesis that AMPK activation may delay disease progression in several cancer types.
Of the 6 studies that used protein expression of p-ACC at Ser79 to characterize AMPK activation, higher p-ACC was associated with worse overall survival (82) and disease recurrence (83) among lung cancer patients, and with worse overall survival among head and neck cancer (75) and kidney cancer(86) patients. In contrast, higher p-ACC was associated with improved overall survival and progression-free survival in colorectal cancer patients (77) . Lastly, no correlation was observed between p-ACC expression and Gleason grade in prostate tumors (71) . A better understanding of the effects of ACC inactivation and its downstream targets in different tumor tissues will help elucidate the complex role of AMPK activation in carcinogenesis.
Tumor expression of specific AMPK α, β, and γ subunits in relation to cancer outcomes has been explored in patients with melanoma (87), kidney cancer (85, 86) , breast cancer (74), cervical cancer (88), lymphoma (89), ovarian cancer (84, 90, 91) , lung cancer (82), and colorectal cancer (92) . Total AMPKα1 protein expression, which captures both phosphorylated and non-phosphorylated AMPKα1, was associated with improved overall and disease-specific survival among 128 melanoma patients (87) .
Total AMPKα1/α2 protein expression was associated with improved progression-free survival (p=0.04) and borderline associated with overall survival (p=0.06) in 37 renal cell carcinoma patients (85) . Using publicly available data from the Cancer Genome Atlas (TCGA), overexpression of the genes encoding for AMPKα1, α2, β1, β2, and γ1 subunits were also associated with improved overall survival (p≤0.05) in 417 clear cell renal cell carcinoma patients (86) . In a discovery (n=166) and validation (n=609) cohort of breast cancer patients, total AMPKα expression was associated with longer relapse-free (p=0.016 and p=0.06, respectively) and breast cancer-specific (p<0.001 and p=0.005, respectively) survival (74) . prostate (63, 71, 72, 96) , and colorectal cancer (92) . In hepatocellular carcinoma, protein expression of p-AMPKα1 at Thr172 was downregulated in 62% of tumor vs. distant normal liver tissue (80) . In ovarian specimens, protein expression of p-AMPKβ1 at Ser182 was significantly higher (p=0.038) in carcinoma compared to borderline tumors and normal ovaries (90). Li et al. also found higher expression of the genes encoding AMPKα2, β1, β2, γ1, and γ2 (p≤0.001), but not AMPKα1 (p=0.320), in primary cancer vs. normal ovarian tissue (91) . In papillary thyroid carcinoma patients, protein expression of total AMPKα, p-AMPKα1 at Thr172, and p-ACC at Ser79 was elevated (p<0.001) in carcinoma vs. paired non-neoplastic tissue (94) . Similarly, protein expression of AMPKα1 was significantly higher (p<0.001) in tumor vs. normal epithelium in cervical cancer patients (95) . In a small study of brain cancer, high protein expression of p-ACC at Ser79 was seen in all glioblastoma specimens compared to absence of expression in normal brain (47) . In melanoma patients, total AMPKα1 protein expression was increased in primary melanoma vs. dysplastic nevi (p<0.005), but slightly decreased in metastatic vs. primary melanoma specimens (p<0.05) (87) . In prostate cancer patients, both p-AMPKα1 at Thr172 and p-ACC at Ser79 were expressed in tumor tissue, compared to no detectable expression in non-paired benign prostate hyperplasia samples (63) . Two additional prostate studies reported elevated expression of p-AMPKα1 at Thr172 and p-ACC at Ser79 (p<0.001) in prostate tumor vs. non-neoplastic tissue (71, 72) .
Utilizing the Oncomine database, the gene encoding AMPKβ1 was expressed at greater levels in metastatic vs. primary prostate cancer in publicly available data from 4 studies (96) . Lastly, expression of the gene encoding AMPKβ1 was significantly higher in colorectal cancer vs. adjacent mucosa (92) .
Taken together, these studies support that AMPK dysregulation contributes to neoplastic transformation. 
n=11 studies; summary RR: 0.82; 95% CI: 0.70-0.96) (101) . Observational studies published after these meta-analyses have either been consistent with reduced cancer risk (102, 103) or null (104) (105) (106) . Overall, the literature suggests that metformin either reduces or has no effect on cancer risk, though very few studies have addressed metformin use in the non-diabetic population. Future clinical trials of metformin therapy in the general population should provide vital data on the potential use of metformin as a chemopreventive agent.
Metformin use may also influence disease progression after a cancer diagnosis. In observational studies, metformin has been associated with a decreased risk of disease recurrence, overall mortality, or cancer-specific mortality in patient cohorts of prostate cancer (107, 108) , multiple myeloma (109), liver cancer (110), ovarian/endometrial cancer (110-112), bladder cancer (113, 114) and breast cancer (115, 116) . Two additional studies of prostate cancer patients who underwent radical prostatectomy found no significant associations between metformin use and time to biochemical recurrence or longer-term outcomes (117, 118) . Two additional studies of breast cancer patients were null for metformin use and overall or cancer-specific survival (119, 120) . Numerous clinical trials of metformin as an adjuvant therapy to cancer treatment are underway as indicated on ClinicalTrials.gov. Combined with the observational data, these new clinical trials will shed light on the potential therapeutic role of metformin in cancer survivors.
In addition, a limited number of 'window of opportunity' (i.e. phase 0) trials have been conducted to evaluate metformin administration in the time window between cancer diagnosis and surgery. These studies show mixed results for tumor p-AMPKα at Thr172 expression before and after metformin use (ranging from 850-2250 mg/day): p-AMPKα protein expression was increased in one study of endometrial cancer patients (121) , decreased in another study of endometrial cancer patients (122) , and unchanged in two studies of endometrial (123) and prostate (124) Phenformin, a metformin analog, is also a potent indirect activator of AMPK and was administered as anti-diabetic medication starting in the mid-1900s. However, increased risk of lactic acidosis, often fatal, led to the withdrawal of phenformin by the US Food and Drug Administration in 1977 (125) . Phenformin has a longer half-life and displays more potent anti-neoplastic activity compared to metformin in in vitro and in vivo pre-clinical studies (126) . In vitro studies of the antitumorigenic effects of metformin are often at supra-physiological concentrations that may be unattainable in humans, thus phenformin may offer an alternative for chemoprevention or adjuvant therapy for cancer patients. Phenformin continues to be available in some parts of the world. In a recent cohort study of biguanide use and colorectal cancer risk in Denmark, phenformin comprised 0.5% of biguanide prescriptions (127) . The investigators analyzed all biguanides as a group and found an increased risk of colorectal cancer among biguanide users compared to non-diabetics, and risk estimates were inconsistent when biguanide users were compared to diabetics on other oral anti-diabetic drugs.
These results conflict with the much of the current literature suggesting a reduced risk or null association for biguanide treatment and colorectal cancer incidence (99) .
More recently, salicylate, the metabolic derivative of aspirin, has been shown to directly activate AMPK (69) . Aspirin has long been known to exhibit antineoplastic properties, though whether these (138)], and prostate cancer (139, 140) patients, while other studies do not (141) (142) (143) (144) .
Overall, the current evidence from long-term observational and randomized studies is strongly suggestive of a potential role for aspirin in the primary and secondary prevention of cancer.
In summary, observational and randomized studies suggest a potential benefit of AMPKactivating drugs for chemoprevention and/or improving cancer survival. These findings are in agreement with associations between AMPK activation levels in tumor tissue and more favorable clinicopathologic features and survival outcomes observed in several cancer types (Table 1) . In future studies, it will be important to understand to what extent AMPK activation mediates the ability of these drugs to reduce cancer risk, and to define their action in the context of the metabolic status of the individual, concurrent medication use, and the natural history of cancer.
Conclusions
The duplicitous role of AMPK activation in cancer cells is context-specific and affects the outcome of 
